Altamira Therapeutics Ltd.
CYTO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $54 | $1,437 | $4,082 | $21,919 |
| - Cash | $999 | $617 | $15 | $984 |
| + Debt | $361 | $100 | $6,331 | $576 |
| Enterprise Value | -$583 | $919 | $10,398 | $21,510 |
| Revenue | – | $0 | $306 | $64 |
| % Growth | – | -100% | 378.4% | – |
| Gross Profit | – | $0 | -$1,138 | -$2,177 |
| % Margin | – | – | -372.4% | -3,407.3% |
| EBITDA | – | -$1,354 | -$17,636 | -$6,716 |
| % Margin | – | – | -5,770.6% | -10,512.8% |
| Net Income | – | -$7,270 | -$26,528 | -$17,058 |
| % Margin | – | – | -8,680.2% | -26,703.1% |
| EPS Diluted | – | -14.8 | -582.58 | -515.11 |
| % Growth | – | 97.5% | -13.1% | – |
| Operating Cash Flow | -$6,114 | -$11,511 | -$8,683 | -$13,673 |
| Capital Expenditures | -$103 | $0 | -$2,143 | -$3,326 |
| Free Cash Flow | -$6,217 | -$11,511 | -$10,826 | -$16,999 |